This article describes the pharmacology of approved parenteral anticoagulants. These include
the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins …

Background : Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over
warfarin which include no need for laboratory monitoring, less drug–drug interactions and …

Background VTE is a common cause of preventable death in surgical patients. Methods We
developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by …

Background It is uncertain whether bridging anticoagulation is necessary for patients with
atrial fibrillation who need an interruption in warfarin treatment for an elective operation or …

The H i Parkes All-Sky Survey (HIPASS) catalogue forms the largest uniform catalogue of H
i sources compiled to date, with 4315 sources identified purely by their H i content. The …

Background Ambulatory patients receiving systemic cancer therapy are at varying risk for
venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is …

… Financial Disclosure: Dr Garcia has received consulting honoraria and research support
from Bristol-Myers Squibb, AstraZeneca, and Sanofi-Aventis. Dr Hylek has served on advisory …

Background: Venous thromboembolism (VTE) is a common source of perioperative morbidity
and mortality. Objective: These evidence-based guidelines from the American Society of …

Venous thromboembolism (VTE) is a serious medical condition associated with significant
morbidity and mortality, and an incidence that is expected to double in the next forty years. …